Elevance Health Reports Q2 2023 Earnings and Future Outlook

Elevance Health reported a net income of $1.45 billion for the second quarter, prompting an upward revision of its annual earnings forecast to a minimum of $20.10 per share. Although this marks a 16.6% decline in net income from the previous year, CEO Gail K. Boudreaux emphasized strong operational performance across its diversified insurance portfolio, including Anthem Blue Cross Blue Shield. Higher medical costs in government programs led to a benefit expense ratio increase to 89.7%, despite improving performance in Affordable Care Act individual plans. Quarterly revenue expanded by 1.4% to $50.47 billion, while total membership fell slightly to 44.9 million.

As the second-largest U.S. health insurer, Elevance manages Blue Cross and Blue Shield plans in 14 states, provides Medicaid services via state contracts, and offers ACA individual coverage. Elevance's Carelon healthcare services also continue to grow. The company's net income was $1.46 billion or $6.71 per share, down from $1.74 billion or $7.72 per share a year earlier. This performance benefitted from enhanced expense management and a below-the-line net benefit of approximately $0.80 per share.

CEO Boudreaux noted the robust second-quarter results as a catalyst for enhancing their guidance, bolstered by disciplined execution and improved healthcare operations. Elevance plans to invest in medical cost management, enhance member experiences, strengthen provider connectivity, and boost operating efficiency with Carelon’s value-based solutions. The target is for adjusted earnings per share growth of at least 12% by 2027. Total revenue growth to $50.47 billion was achieved through increased premium yields and CarelonRx product revenue, despite anticipated drops in Medicare Advantage, Medicaid, and Employer Group memberships. As of the quarter's end, membership stood at 44.9 million, compared to 45.6 million the previous year.